Mepolizumab in Urban Children With Exacerbation-Prone Eosinophilic Asthma in the US
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial
Lancet 2022 Aug 13;400(10351)502-511, DJ Jackson, LB Bacharier, PJ Gergen, L Gagalis, A Calatroni, S Wellford, MA Gill, J Stokes, AH Liu, RS Gruchalla, RT Cohen, M Makhija, GK Khurana Hershey, GT O'Connor, JA Pongracic, MG Sherenian, K Rivera-Spoljaric, EM Zoratti, SJ Teach, M Kattan, CM Dutmer, H Kim, C Lamm, WJ Sheehan, RM Segnitz, KA Dill-McFarland, CM Visness, PM Becker, JE Gern, CA Sorkness, WW Busse, MC AltmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.